Newsbenzinga
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
· Published
Article summary
Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.
An excerpt from the original article.
Comments —
Loading comments…